Information from the Annual General Meeting | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

May 2019

Information from the Annual General Meeting

The Annual General meeting was held on the 28th of May 2019.

Read the information here (in swedish).

IDL Biotech signs distributor agreement in Ghana

IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech

Skip this intro